WuXi AppTec
WuXi AppTec is a global pharmaceutical, biopharmaceutical, and medical device outsourcing company.
WuXi AppTec, founded in December, 2000 and headquartered in Wuxi, is Ge Li. The founder is Ge Li. Listed on the HKEX on December 13, 2018, the company's major shareholders are HKSCC Nominees Ltd, G&C VI Ltd and Summer Bloom Investments (I) PTE. Ltd. Rivals that have direct and indirect competition with WuXi AppTec include Kintor, HitGen, Aprea Therapeutics, BridgeBio Pharma, etc.
Cancer cell therapy company raised CNY 500 million in D round
Baiji Shenzhou PD-1 inhibitor price dropped by 80%
Novozyme plus R-CHOP Regimen for first-line treatment of mantle cell lymphoma
Bh009 new drug project independently researched and developed by Beihai biological Co., Ltd. was approved by China's clinical trials
Research
Technology, Healthcare, Consumer StaplesWIA2020 | Rising Tech Stars 2020: Global & China's 100
Research
Industrials, Financials, Consumer StaplesTech for Global, Globalization Footprints of the Established and the New
Research
Industrials, Financials, Consumer StaplesLow-Carbon Industry Expansion - Key Studies From Chinese Companies
Qiuzhen medical and tianguangshi have reached strategic cooperation to develop diagnostic kits and tumor drugs
Sinopharm new coronavirus vaccine approved
Another protein component special medical food was approved, and the total number of approved products increased to 57
Phase I project of Guangzhou Pharmaceutical production base of nuocheng Jianhua was completed
Revenue and Net Profit of Wuxi Apptec Both Increased in 2020
Wuxi apptec said that the main reasons for the company's performance growth were the high growth of laboratories in China and the year-on-year growth of CDMO plate. China laboratory service is the core business of Wuxi apptec, accounting for more than 50% of its revenue. Its main business is small molecule drug discovery, drug analysis and testing.
Apr 01, 2021 04:39 PM
BGI and Hanwei intelligent medical jointly launched mobile "two cancer" intelligent screening
Asc41, a candidate drug for NASH, was administered to overweight and obese subjects in phase IB clinical trial
Fosun medicine: the new crown vaccine has been included in the domestic phase II clinical, and no serious adverse report has been received
JW Therapeutics Studys on Adoptive T-cell Therapy with Lyell Immunopharma
TigerMed: New to be the Third Dual-listed CRO on HKEX and A-share
JW Therapeutics Buys Hong Kong Anti-cancer Drug Maker Syracuse Biopharma
JW Therapeutics’s CAR-T Therapy Goes Public, Second Candidate after FosunKite Biotech